The aim of this study was to evaluate the factors affecting the response to treatment and how it could affect survival in a large series of genotype-1 HCV-transplanted patients. Three-hundred and twenty six genotype-1 HCV patients were enrolled. One hundred and ninety-six patients (60.1%) were nonresponders and 130 (39.9%) showed negative HCV-RNA at the end of treatment. Eighty-four of them (25.8%) achieved sustained virological response, while 46 (14.1%) showed viral relapse. Five-year cumulative survival was significantly worse in nonresponders (76.4%) compared with sustained viral response (93.2) or relapsers (94.9%). Sustained responders and relapsers were therefore considered as a single 'response group' in further analysis. Pretreatment variables significantly associated with virological response at multivariate regression analysis were the absence of ineffective pretransplant antiviral therapy, the recurrence of HCV-hepatitis more than 1 year after transplant, an histological grading ≥4 at pretreatment liver biopsy, a pretreatment HCV-RNA level <1.2 × 106IU/ml, and the absence of diabetes. As expected, also on-treatment variables (rapid and early virological response) were significantly associated to the response to antiviral treatment. In conclusion, this study shows that postliver transplant antiviral treatment results in beneficial effect on survival not only in sustained responders but also in relapsers.

Ponziani, F., Milani, A., Gasbarrini, A., Zaccaria, R., Viganò, R., Iemmolo, R., et al. (2013). Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers. TRANSPLANT INTERNATIONAL, 26(3), 281-289 [10.1111/tri.12027].

Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers

Fagiuoli S;
2013

Abstract

The aim of this study was to evaluate the factors affecting the response to treatment and how it could affect survival in a large series of genotype-1 HCV-transplanted patients. Three-hundred and twenty six genotype-1 HCV patients were enrolled. One hundred and ninety-six patients (60.1%) were nonresponders and 130 (39.9%) showed negative HCV-RNA at the end of treatment. Eighty-four of them (25.8%) achieved sustained virological response, while 46 (14.1%) showed viral relapse. Five-year cumulative survival was significantly worse in nonresponders (76.4%) compared with sustained viral response (93.2) or relapsers (94.9%). Sustained responders and relapsers were therefore considered as a single 'response group' in further analysis. Pretreatment variables significantly associated with virological response at multivariate regression analysis were the absence of ineffective pretransplant antiviral therapy, the recurrence of HCV-hepatitis more than 1 year after transplant, an histological grading ≥4 at pretreatment liver biopsy, a pretreatment HCV-RNA level <1.2 × 106IU/ml, and the absence of diabetes. As expected, also on-treatment variables (rapid and early virological response) were significantly associated to the response to antiviral treatment. In conclusion, this study shows that postliver transplant antiviral treatment results in beneficial effect on survival not only in sustained responders but also in relapsers.
Articolo in rivista - Articolo scientifico
antiviral treatment; genotype-1; hepatitis C recurrence; hepatitis C virus; liver transplant; pegylated interferon; responders; ribavirin; survival;
English
281
289
9
Ponziani, F., Milani, A., Gasbarrini, A., Zaccaria, R., Viganò, R., Iemmolo, R., et al. (2013). Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers. TRANSPLANT INTERNATIONAL, 26(3), 281-289 [10.1111/tri.12027].
Ponziani, F; Milani, A; Gasbarrini, A; Zaccaria, R; Viganò, R; Iemmolo, R; Donato, M; Rendina, M; Toniutto, P; Pasulo, L; Cescon, M; Burra, P; Miglioresi, L; Merli, M; Paolo, D; Fagiuoli, S; Pompili, M
File in questo prodotto:
File Dimensione Formato  
transpl Intern_2013.pdf

Solo gestori archivio

Dimensione 109.59 kB
Formato Adobe PDF
109.59 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/354075
Citazioni
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 8
Social impact